Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GDTC | 6-K | neutral | 3/10 | CytoMed Therapeutics announced the name change of its wholly owned subsidiary from Advance Cancer Centre Pte. Ltd. to Cy | May 11, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine announced a live webinar on June 10, 2026, to discuss early clinical data from its Phase I/IIa trial | May 11, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three insiders at United Therapeutics sold a total of $377K in open-market sales over a 7-day window, immediately follow | May 11, 2026 |
| NTLA | 8-K | mixed | 6/10 | Intellia reported Q1 2026 results with a net loss of $96.2M ($-0.81/share), narrower than the $114.3M loss in Q1 2025, w | May 11, 2026 |
| DYN | 8-K | neutral | 5/10 | Dyne Therapeutics reported Q1 2026 net loss of $120.9M ($0.73/share), wider than the $115.4M loss in Q1 2025 but narrowe | May 11, 2026 |
| BCAX | 8-K | neutral | 4/10 | Bicara Therapeutics reported Q1 2026 net loss of $56.2M ($-0.93/share), wider than the $-0.68 loss in Q1 2025, driven by | May 11, 2026 |
| ATHE | PRESS-RELEASE | bullish | 7/10 | Alterity Therapeutics announced a peer-reviewed publication in NeuroImage demonstrating that QSM MRI can detect disease- | May 11, 2026 |
| APGE | 8-K | bullish | 7/10 | Apogee Therapeutics reported Q1 2026 results with a net loss of $74.1M, wider than the $55.3M loss in Q1 2025, driven by | May 11, 2026 |
| LXEO | 8-K | bullish | 6/10 | Lexeo Therapeutics reported Q1 2026 results with a net loss of $20.2M ($0.25 per share), narrowing from $32.7M ($0.99 pe | May 11, 2026 |
| APGE | PRESS-RELEASE | bullish | 7/10 | Apogee Therapeutics reported Q1 2026 EPS of -$1.03, a 9% beat vs consensus of -$1.13, with no revenue. The company highl | May 11, 2026 |
| LXEO | PRESS-RELEASE | bullish | 6/10 | Lexeo Therapeutics reported Q1 2026 net loss of $0.25 per share, beating consensus estimates of -$0.30 by 16.7%, with re | May 11, 2026 |
| GANX | PRESS-RELEASE | neutral | 4/10 | Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat is marginal for a pr | May 11, 2026 |
| MBX | PRESS-RELEASE | mixed | 6/10 | MBX Biosciences reported preliminary Phase 1 data for MBX 4291 (GLP-1/GIP co-agonist prodrug) showing 7% mean weight los | May 11, 2026 |
| ERAS | PRESS-RELEASE | neutral | 4/10 | Erasca announced a clinical trial collaboration with Merck to evaluate its pan-RAS molecular glue ERAS-0015 in combinati | May 11, 2026 |
| LQDA | 8-K | bullish | 8/10 | Liquidia Corp reported Q1 2026 results with YUTREPIA net product sales of $129.9M, net income of $52.9M ($0.52 diluted E | May 11, 2026 |
| GLAXF | 6-K | neutral | 4/10 | GSK announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) via its subsidiary CTTQ to co | May 11, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK announced the fifth and final tranche of its £2 billion share buyback programme, with up to approximately £0.18 bill | May 11, 2026 |
| LQDA | PRESS-RELEASE | bullish | 7/10 | Liquidia reported Q1 2026 revenue of $132.9M (driven by YUTREPIA sales of $129.9M) and net income of $52.9M ($0.52 dilut | May 11, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech announced that the FDA completed a routine cGMP surveillance inspection of its Reykjavik facility, issuing a Fo | May 11, 2026 |
| ALVO | PRESS-RELEASE | bullish | 6/10 | Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issuing a Form 483 with o | May 11, 2026 |
| MLTX | PRESS-RELEASE | bullish | 7/10 | MoonLake announced a successful final pre-BLA meeting with the FDA, aligning on submission plans and label strategy for | May 10, 2026 |
| SNY | COURT-RULING | neutral | 3/10 | A federal district court partially denied Sanofi's motion to dismiss an employment discrimination lawsuit, allowing race | May 10, 2026 |
| SYRE | CLUSTER | neutral | 3/10 | Four insiders at Spyre Therapeutics, including the CEO, CFO, and CMO, sold a total of $2.92M in open-market sales over a | May 8, 2026 |
| ISPC | PRESS-RELEASE | bearish | 6/10 | iSpecimen priced a ~$2.5M private placement, issuing 488,281 shares at $5.12/share with pre-funded warrants, for working | May 8, 2026 |
| APGE | CLUSTER | neutral | 2/10 | Two C-suite insiders at Apogee Therapeutics sold a combined $377K in stock over a 7-day window, representing less than 0 | May 8, 2026 |
| EXEL | CLUSTER | neutral | 2/10 | Two Exelixis directors sold a combined $3.12M in open-market transactions following a strong Q1 2026 earnings beat (reve | May 8, 2026 |
| ARVN | 144 | neutral | 2/10 | Officer Andrew Saik filed Form 144 to sell 11,343 shares of Arvinas common stock (approx. $114,678) to cover withholding | May 8, 2026 |
| ARVN | 144 | neutral | 2/10 | Noah Berkowitz, an officer of Arvinas, filed a Form 144 to sell 11,312 shares (approx. $114K) on May 11, 2026, solely to | May 8, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gM | May 8, 2026 |
| SVA | 6-K | bearish | 7/10 | Sinovac reported flat revenue of $130.3M for H1 2025, but swung from a $93.9M profit to a $21.7M net loss, driven by $68 | May 8, 2026 |